Excessive poly(ADP-ribose) (PAR) polymerase-1 (PARP-1) activation kills cells via a cell-death process designated "parthanatos" in which PAR induces the mitochondrial release and nuclear translocation of apoptosis-inducing factor to initiate chromatinolysis and cell death. Accompanying the formation of PAR are the reduction of cellular NAD + and energetic collapse, which have been thought to be caused by the consumption of cellular NAD + by PARP-1. Here we show that the bioenergetic collapse following PARP-1 activation is not dependent on NAD + depletion. Instead PARP-1 activation initiates glycolytic defects via PAR-dependent inhibition of hexokinase, which precedes the NAD + depletion in N-methyl-N-nitroso-N-nitroguanidine (MNNG)-treated cortical neurons. Mitochondrial defects are observed shortly after PARP-1 activation and are mediated largely through defective glycolysis, because supplementation of the mitochondrial substrates pyruvate and glutamine reverse the PARP-1-mediated mitochondrial dysfunction. Depleting neurons of NAD + with FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, does not alter glycolysis or mitochondrial function. Hexokinase, the first regulatory enzyme to initiate glycolysis by converting glucose to glucose-6-phosphate, contains a strong PAR-binding motif. PAR binds to hexokinase and inhibits hexokinase activity in MNNG-treated cortical neurons. Preventing PAR formation with PAR glycohydrolase prevents the PAR-dependent inhibition of hexokinase. These results indicate that bioenergetic collapse induced by overactivation of PARP-1 is caused by PAR-dependent inhibition of glycolysis through inhibition of hexokinase.
by the consumption of cellular NAD + by PARP-1. Here we show that the bioenergetic collapse following PARP-1 activation is not dependent on NAD + depletion. Instead PARP-1 activation initiates glycolytic defects via PAR-dependent inhibition of hexokinase, which precedes the NAD + depletion in N-methyl-N-nitroso-N-nitroguanidine (MNNG)-treated cortical neurons. Mitochondrial defects are observed shortly after PARP-1 activation and are mediated largely through defective glycolysis, because supplementation of the mitochondrial substrates pyruvate and glutamine reverse the PARP-1-mediated mitochondrial dysfunction. Depleting neurons of NAD + with FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, does not alter glycolysis or mitochondrial function. Hexokinase, the first regulatory enzyme to initiate glycolysis by converting glucose to glucose-6-phosphate, contains a strong PAR-binding motif. PAR binds to hexokinase and inhibits hexokinase activity in MNNG-treated cortical neurons. Preventing PAR formation with PAR glycohydrolase prevents the PAR-dependent inhibition of hexokinase. These results indicate that bioenergetic collapse induced by overactivation of PARP-1 is caused by PAR-dependent inhibition of glycolysis through inhibition of hexokinase. P harmacological inhibition or genetic deletion of poly(ADPribose) polymerase-1 (PARP-1) is dramatically protective against a variety of toxic insults including ischemia reperfusion injury in the heart, brain, and other organs (1, 2) . PARP-1 activation also may play a role in several neurologic disorders such as Parkinson disease (PD), Alzheimer's disease (AD), autoimmune encephalomyelitis, and multiple sclerosis (3) (4) (5) . PARP-1 activation plays a prominent role in necrotic cell death; the necrotic cell-death program initiated by PARP-1 activation has been designated "parthanatos" to distinguish it from other forms of cell death (6, 7) . Cell death via PARP-1 activation is thought to occur through the formation of poly(ADP-ribose) (PAR), which acts as a death signal to cause the release of apoptosisinducing factor (AIF) from the mitochondria (8) (9) (10) . AIF then translocates to the nucleus, causing nuclear condensation, genomic DNA fragmentation, and cell death (9, 10) .
One of key features of parthanatos is consumption of NAD + caused by parylation, the addition of PAR on PARP-1 itself and ribosylation of PARP-1 substrates (6, 11) . Accompanying the NAD + -dependent parylation is a drop in cellular ATP levels and metabolic collapse that have been ascribed to the consumption of NAD + and subsequent restoration of NAD + levels, requiring four ATP molecules for each NAD + molecule (12) . Early studies suggested that the decrements in NAD + and ATP led to cell death through energy collapse (12) (13) (14) . However, many studies have challenged this notion, because cell death has been shown to be independent of the loss of cellular energy stores (11, 15, 16) but dependent on PAR signaling (8) (9) (10) (11) . In cells lacking the PAR-degradative enzyme PAR glycohydrolase (PARG), activation of PARP-1 leads to cell death that does not require NAD + depletion. Instead, cell death occurs through PAR activation of parthanatos (17, 18) . In addition, reductions in ATP levels have been shown to precede the reduction in NAD + , thus challenging the idea that the reduction in ATP is caused by the consumption of NAD + (15, 16) . Thus the initiator of the mechanism underlying the decrements in ATP after PARP-1 activation is not known. Here we show that that the bioenergetic collapse after PARP-1 activation is not dependent on NAD + depletion but instead is caused by the PAR-dependent inhibition of glycolysis that occurs through the inhibition of hexokinase (HK). This study suggests that pharmacological interventions independent of NAD + are potential targets to prevent bioenergetic defects and cell death in diseases that involve PARP-1 activation.
Results

PARP Activation Induces Defects in Glycolysis.
To analyze the effects of PARP-1 activation on glycolysis, a comprehensive real-time analysis of glycolytic flux was assessed via an XF24 Seahorse Flux Analyzer (Seahorse Bioscience) in N-methyl-N-nitroso-N′-nitroguanidine (MNNG)-treated mouse cortical neurons in the presence and absence of the potent PARP inhibitor 3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) (Fig. 1) . MNNG is a potent, widely used activator of PARP (11, 19) . Treatment of cortical neurons with 50 μM MNNG for 15 min induces PARP activation as determined by PAR formation via an antibody to PAR (Fig. 1A) . PAR is detected immediately Significance Excessive activation of poly(ADP-ribose) (PAR) polymerase (PARP) is intimately linked to cell death in a variety of organ systems. It has long been thought that the cell death caused by excessive activation of PARP occurs through the catalytic consumption of NAD + followed by reduction of ATP and bioenergetic collapse. This study shows that the bioenergetic collapse is caused not by the consumption of NAD + but by PARdependent inhibition of hexokinase activity leading to defects in glycolysis. These results are consistent with the notion that cell death induced by excessive PARP activity (parthanatos) is an active cell-death program that is initiated by PAR signaling. after the 15-min treatment of cortical neurons with MNNG and is present for at least 60 min after MNNG administration. DPQ completely prevents the formation of PAR, as previously described (8) (Fig. 1A) . Cell death monitored by Hoechst and propidium iodide staining 24 h after MNNG treatment is dependent on PARP-1, because DPQ prevents cell death, as previously described (8) (Fig. 1B) . Under these conditions, glycolytic flux (basal glycolysis, glycolytic capacity, and glycolytic reserve) as assessed by the extracellular acidification rate (ECAR) was analyzed by the sequential addition of glucose, oligomycin, and 2-deoxyglucose in glucose-free Seahorse assay medium (Fig. 1C) .
Basal glycolysis is inhibited significantly 1 h after the 15-min MNNG treatment (Fig. 1D) , whereas the maximal glycolytic capacity (Fig. 1E ) and reserve glycolysis (Fig. 1F ) are abolished almost completely by MNNG. DPQ completely preserved the glycolytic function in MNNG-treated neurons (Fig. 1C) . To determine whether these defects in glycolysis are caused by PAR formation, cortical neurons were transduced with an adenovirus expressing the PAR-degrading enzyme PARG (8, 10) . Glycolysis was assessed via lactate production (20, 21) in the MNNG-treated mouse cortical neurons. MNNG induces a 58% reduction in lactate levels that is prevented by PARG and DPQ (Fig. 1G) . Taken together, these results suggest that PARP-1 activation causes severe defects in glycolysis that are mediated by PAR.
PARP Activation Causes Mitochondrial Dysfunction. To determine whether PARP-1 activation causes mitochondrial dysfunction, we monitored the mitochondrial oxygen consumption rate (OCR) in mouse cortical neurons treated with MNNG ( Fig. 2A) . Basal mitochondrial OCR is decreased significantly in MNNGtreated cortical neurons, and DPQ completely rescues the reduction in OCR (Fig. 2B ). MNNG induces a significant reduction in maximal OCR (Fig. 2C) and completely abolishes the reserve respiratory capacity (Fig. 2D) . DPQ substantially protects against these MNNG-induced defects in mitochondrial respiration. Interestingly, the mitochondrial electron transport chain appears to be intact, because there are no apparent proton leaks 1 h after MNNG treatment (Fig. 2E ). These results are in agreement with previously published studies in which Krebs cycle intermediates rescue neurons from PARP-1-dependent cell death (22) . Moreover, these observations suggest that the changes in mitochondrial OCR may be caused primarily by the reduced availability of substrates for mitochondrial oxidative phosphorylation and not by defective mitochondrial function. Mitochondrial function is directly dependent on glycolytically derived pyruvate (23) , which is a substrate for oxidative phosphorylation (23, 24) . To assess whether the impaired OCR is caused by the reduced availability of pyruvate, we supplemented pyruvate to bypass the intermediate steps in glycolysis in the assay medium containing glutamine and assessed OCR (Fig. 2F ). The addition of pyruvate to the assay medium completely preserved the basal mitochondrial OCR in MNNG-treated neurons (Fig. 2G) . Similarly, the maximal OCR and reserve capacity were preserved significantly by pyruvate in MNNG-treated neurons ( Fig. 2 H and I ). These data show that PAR can cause a reduction in mitochondrial function because of the reduced availability of glycolytically derived pyruvate.
Glycolytic Defects Caused by PARP Activation Do Not Require NAD + Depletion. NAD + levels were monitored after treatment of cortical neurons with 50 μM MNNG for 15 min. There was no appreciable change in NAD + levels between 0 and 30 min after MNNG treatment (Fig. 3A) , when there was robust evidence of PAR formation (Fig. 1A ), but NAD + levels were decreased significantly at 1 h (Fig. 3A) and remained depressed up to 6 h after the MNNG treatment (Fig. 3A) . Glycolytic function was assessed 15, 30, and 45 min after MNNG treatment, time points at which there is no appreciable loss of NAD + levels, and at 60 min after MNNG treatment (Fig. 3B ). Glycolytic function was reduced significantly at 15 min and was reduced further at 30 and 45 min after MNNG treatment, with no further reduction at 60 min (Fig. 3B ). ATP levels were reduced following MNNG treatment, paralleling the reduction in glycolytic function (Fig.  3C ). Of note, the decrease in ATP levels occurs before a significant loss of NAD + . DPQ completely prevents the decrease in glycolytic function and ATP levels at all time points.
To confirm that the defects in glycolysis and mitochondrial respiration are not caused by a reduction in NAD + levels, FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, was used to decrease NAD + levels independent of PARP activation (25) . Treatment of cortical neurons with FK866 leads to a decrease in NAD + levels (Fig. 4A ) Celldeath assessment in mouse cortical neurons treated with MNNG ± DPQ. Cell death was assessed using propidium iodide and Hoechst staining. n = 6; *P < 0.01 vs. control. (C) ECAR analysis in MNNG-treated cortical neurons. Cortical neurons were treated with MNNG for 15 min; then medium was replaced with glucose-free Seahorse medium for ECAR analysis. n = 6; *P < 0.01 vs. control. (D) Basal ECAR was calculated relative to the DMSO control. After the nonglycolytic ECAR was subtracted, the basal ECAR was 20.97 ± 4.2, 10.15 ± 1.5, and 20.34 ± 3.4 milli-pH (mpH)·min −1 ·100 μg protein −1 for DMSO-, MNNG-, and MNNG + DPQ-treated cultures, respectively. n = 6; *P < 0.01 vs. control. (E) Maximal glycolysis after the addition of oligomycin was calculated relative to DMSO control. After the nonglycolytic ECAR was subtracted, the maximal ECAR was 34.36 ± 4.6, 10.2 ± 1.5, and 25.10 ± 2.4 mpH·min −1 ·100 μg protein −1 in DMSO-, MNNG-, and MNNG + DPQ-treated cultures, respectively. n = 6; *P < 0.01 vs. control. (F) Glycolytic reserve capacity in cortical neurons treated with MNNG ± DPQ. After the nonglycolytic ECAR was subtracted, the reserve ECAR was 13.39 ± 2.7, 1.05 ± 1.3, and 5.87 ± 2.5 mpH·min equivalent to those induced by MNNG treatment. FK866 fails to activate PARP under these conditions, as determined by PAR immunoblot analysis (Fig. 4B) , and it fails to reduce ATP levels (Fig. 4C) . In contrast, MNNG treatment leads to PAR activation (Fig. 1A) , decreases NAD + levels (Fig. 3A) , and reduces ATP levels (Fig. 3C ). Glycolytic flux (basal glycolysis, glycolytic capacity, and glycolytic reserve) as assessed by ECAR was analyzed by the sequential addition of glucose, oligomycin, and 2-deoxyglucose in glucose-free Seahorse assay medium 5 h after FK866 treatment, when NAD + levels are significantly decreased (Fig. 4 A and D) . Under these conditions FK866 did not cause any changes in basal glycolysis (Fig. 4 D and E) , maximal glycolytic capacity, or reserve glycolysis (Fig. 4 D and F) . Mitochondrial OCR also was monitored in mouse cortical neurons treated with FK866 (Fig. 4G) . FK866 did not cause any changes in basal or maximal mitochondrial OCR (Fig. 4 H and I) . Thus, NAD + depletion induced by FK866 does not cause glycolytic or mitochondrial defects as assessed by ECAR and OCR analysis.
PARP Activation Inhibits HK. To identify how PARP activation inhibits glycolysis, glycolytic proteins were examined for PARbinding domains including the PAR-binding motif (PBM), the PAR-binding zinc finger (PBZ) domain, the macro domain, and the WWE domain, a domain with conservative multiple sequence alignment of two tryptophan (W) and a glutamate (E) residues (26) . HK-1 and HK-2 contain a strong PBM, as previously described (27) (Fig. 5A) . Because HK catalyzes the first regulatory step in glycolysis (28), HK activity was assessed in MNNG-treated cortical neurons. MNNG treatment of cortical neurons leads to a significant reduction in HK activity 15 min after the MNNG treatment (Fig. 5B) , when defects in glycolysis are observed (Fig. 3B ), but NAD + levels are not reduced (Fig.  3A) . HK activity continues to decrease after MNNG treatment (Fig. 5B) , similar to the reduction in glycolysis (Fig. 3B) . The reduction in HK activity is reversed by pretreatment with DPQ (Fig. 5B) . In addition, MNNG does not reduce the total HK levels, as determined by Western blot (Fig. 5C ). To determine whether PAR inhibits HK activity, an in vitro HK enzymatic assay was performed in neuronal cell lysates in the presence of PAR or predigested PAR with PARG as a control. PAR directly inhibits HK activity, but PARG-digested PAR is not able to inhibit HK activity (Fig. 5D) . Besides serving as an essential glycolytic enzyme, HK activity also is required to maintain redox homeostasis via the pentose phosphate pathway (20, 21, 29) . Pentose phosphate pathway-dependent redox homeostasis is a critical cell survival pathway required to maintain adequate levels of the antioxidant glutathione (GSH) (20, 21, 29) . Accordingly, NADPH and GSH levels were monitored as additional indices of HK activity in mouse cortical neurons 1 h after MNNG treatment. Both NADPH and GSH levels were decreased significantly by MNNG treatment, and DPQ prevented the decrements in NADPH and GSH (Fig. 5E ). To determine whether PAR binds to HK, cortical neurons were treated with MNNG and immunoprecipitated with a PAR antibody (Fig. 5F ). PAR coimmunoprecipitated HK-1 from cortical neurons following MNNG treatment (Fig. 5G) . Taken together, these results suggest that the reduction in HK activity is PARP dependent and potentially occurs in a PAR-dependent manner.
Discussion
The major finding of this article is that PARP activation leads to inhibition of glycolysis that is not dependent on NAD + depletion. PARP activation causes significant decrements in glycolytic flux as determined by a significant reduction in basal glycolysis, glycolytic capacity, glycolytic reserve, and lactate production. Moreover, there are PARP-dependent reductions in mitochondrial function as determined by mitochondrial OCR and reserve respiratory capacity. These reductions in glycolytic and mitochondrial function occur before the reduction in NAD + , suggesting that the reduction in NAD + levels is not responsible for the bioenergetics failure that occurs after PARP activation. Consistent with this notion are the observations that reducing NAD + levels, via inhibition of nicotinamide phosphoribosyltransferase with FK866, equivalent to the reduction of NAD + levels following PARP activation, does not cause any defects in glycolysis and mitochondrial function. Prior studies postulated that NAD + depletion was responsible for the glycolytic and bioenergetics failure in PARP-1 activation (22, 30) . Our data, on the other hand, suggest that NAD + depletion does not play a major role in the glycolytic and bioenergetics failure. Moreover, the mitochondrial dysfunction is not caused by direct damage to mitochondria by PARP action, because the mitochondrial electron transport chain is intact because there are no proton leaks. These results are in agreement with previously published studies showing that Krebs cycle intermediates rescue neurons from PARP-1-dependent cell death (22) . Because pyruvate and glutamine completely restore the defects in mitochondrial function, the changes are likely to be caused by the defects in glycolysis and by the decreased availability of substrates for mitochondrial oxidative phosphorylation. We cannot exclude the possibility that the NAD + depletion ·100 μg protein −1 in DMSO-treated cultures and 6.69 ± 1.2 in FK866-treated cultures. n = 9. (F) The maximal ECAR after the addition of oligomycin was calculated relative to control. After the nonglycolytic ECAR was subtracted, the ECAR was 14.75 ± 0.6 and 13.2 ± 1.5 mpH·min· contributes to and maintains the glycolytic and bioenergetics failure after the defects are set in motion by PAR via PARP activation.
Our results indicate that PARP activation leads to a decrement in HK activity. Because studies suggest that PARP activation plays an important role in many pathophysiological states, including stroke, PD, and AD (3) (4) (5) , it is likely that PARPdependent HK inhibition plays a role in the pathophysiology of these disorders. In support of this notion, redistribution and a decrease in HK activity has been shown to play a critical role in oxidative stress and neurodegeneration in AD (31) . Similarly, overexpression of HK protects against neurodegeneration in mouse models of PD (32) . Future studies are needed to explore whether PAR-induced HK inhibition occurs in other pathophysiological states associated with PARP activation, but past studies with MNNG suggest that our findings should extend to many if not all pathophysiological states associated with PARP activation.
The decrement in HK activity observed with PARP activation likely accounts for the decreased glycolytic flux. HK is the first regulatory enzyme in glycolysis that converts glucose into glucose 6-phosphate (23) . Glucose 6-phosphate is required for glycolysis, and it is also an important substrate for maintaining NADPH and GSH levels via the pentose phosphate pathway. Importantly HK is inhibited by PARP activation, and the time course of inhibition parallels the decrements in glycolysis and mitochondrial function that are observed after PARP activation. HK contains a PBM, and after PARP activation it coimmunoprecipitates with PAR, indicating that it is a PAR-binding protein. PAR directly inhibits HK, as indicated by the in vitro HK enzymatic assay. Because of HK's critical role in glycolysis and maintaining bioenergetics, it is highly probable that direct binding of PAR to HK after PARP activation leads to its inhibition and the subsequent reductions in glycolysis and bioenergetics. It is likely that inhibition of PAR binding to HK via blocking peptides or small molecular inhibitors could prevent the energy deficits induced by PARP activation.
Previously it was shown that PARP activation leads to cell death via parthanatos, a process involving the PAR-dependent release of AIF from the mitochondria. Because AIF and HK interact (33, 34) , it is conceivable that the PAR-induced release of AIF could contribute to reductions in HK activity and subsequent glycolytic and bioenergetics defects. Future studies are required to sort out the importance of the AIF, HK, and PAR interactions in parthanatos.
In summary, we report that PARP activation leads to NAD + -independent glycolytic and bioenergetic failure that likely is caused by the inhibition of HK by PAR. These observations provide important insights into cell death mechanisms that are induced by PARP activation.
Materials and Methods
More detailed information on the materials and methods is provided in SI Materials and Methods.
Primary Neuronal Culture Preparation. Primary cortical cell cultures were prepared as previously described (35) .
Measurements of OCR.
Mitochondrial OCR in mouse cortical neurons was measured in an XF24 Extracellular Flux Analyzer (Seahorse Bioscience), as described previously (36) (37) (38) .
Measurement of Glycolysis as ECAR. Glycolytic flux (basal glycolysis, glycolytic capacity, and glycolytic reserve) as assessed by ECAR were analyzed by the sequential addition of glucose, oligomycin, and 2-deoxyglucose in an XF24 flux analyzer (Seahorse Biosciences) as previously described (37) .
Immunoblot Analysis. Immunoblots were performed on neuronal culture lysates after exposure to MNNG for 15 min and thereafter collected at 0, 15, 30 and 60 min in lysis buffer.
Immunoprecipitation. Fifteen minutes after MNNG treatment, neuronal cultures from a six-well plate (Nunc Thermo Scientific) were collected in 0.5 mL lysis buffer (PBS containing 1 mM EDTA, 1 mM EGTA, 0.5% SDS, 1% Nonidet P-40, 0.25 mM sodium orthovanadate, 0.25 mM PMSF, 2.5 μg/mL leupeptin, NADPH was estimated using an NADP/NADPH assay kit (catalog no. ab65349; Abcam). Reduced GSH was quantified by HPLC using a C18 column. Samples for GSH estimation were collected 1 h after MNNG treatment. The GSH level was 321.40 ± 8.62 ng/mg protein in DMSO-treated cultures, 180.08 ± 40.07 ng/mg protein in MNNG-treated cultures, and 281 ± 36.8 ng/mg protein in MNNG + DPQ-treated cultures. n = 3; *P < 0.05 vs. control. (F) Immunoprecipitation of PAR using a custom-made PAR monoclonal antibody (clone #21) in mouse cortical neurons. PAR formation was stimulated by MNNG treatment for 15 min, and samples were collected 15 min after MNNG washout. PAR blots were developed using PAR antibody (clone #19). (G) Immunoblots show coimmunoprecipitation of HK-1 with PAR. Neuronal cultures were treated with MNNG for 15 min, and samples were collected 15 min after MNNG washout. PAR antibody (clone #21) was used to immunoprecipitate PAR, and the blots were developed with HK-1 antibody after SDS/PAGE and Western blotting on a nitrocellulose membrane.
2.5 μg/mL aprotinin) and incubated for 30 min at 4°C with constant agitation. After centrifugation (10,000 × g, 4°C for 10 min), the resulting supernatants were subjected to immunoprecipitation by incubation at 4°C overnight with a preformed complex of Pure ProteomeTM Kappa IgG binder magnetic beads (Millipore) and an anti-PAR antibody (clone #21, custom designed at Bio-Rad, AbD Serotec GmbH). After overnight incubation at 4°C, the samples were washed three times with Tris-buffered saline containing 0.1% Tween 20, and the samples were eluted with Laemmli sample loading buffer (Bio-Rad Laboratories) and subsequent heating at 100°C for 5 min. The eluted samples were run on an SDS/PAGE, and Western blots were developed using anti-PAR (clone #19, custom designed at Bio-Rad, AbD Serotec GmbH), anti-HK-1 (Cell Signaling) primary antibodies, and HRP goat anti-human IgG (Fab')2 (Abcam) and HRP donkey anti-rabbit IgG (GE Healthcare) secondary antibodies. The immunoblots were visualized with enhanced chemiluminescence (Pierce) in an ImageQuant LAS 4000 mini imaging analyzer (GE Healthcare).
NAD
+ and ATP Measurements. NAD + was measured using a NAD/NADH quantification KIT (Sigma) after treatment with 50 μM MNNG for 15 min in the presence or absence of DPQ or 10 μM FK866 or DMSO.
HK Activity Assay. HK activity was measured according to the Worthington protocol (Worthington Biochemical Corp.) with slight modifications.
Generation of PAR Antibodies from the HuCAL Platinum Library. Antibodies against PAR polymer were generated using the Human Combinatorial Antibody Library (HuCAL) platform (Bio-Rad AbD Serotec, Germany). HuCAL consists of billions of recombinant human Fab antibodies to generate highly specific monoclonal antibodies. Purified PAR was purchased from Trevigen Inc., and highly specific antibodies were generated using HuCAL technology at AbD Serotec. The panning in HuCAL technology involves phage display selection that consists of antigen (PAR) immobilization on magnetic beads, followed by HuCAL library incubation and removal of nonspecific antibodies. In this case, all antibodies that detect free ADP ribose were removed. Phages encoding antibodies specific for PAR were amplified, and highly specific human monoclonal recombinant antibodies were generated (AbD Serotec). Multiple highly specific clones detecting PAR were screened in both human and mouse cells. Here we used clones #21 and #19.
Statistical Analysis. One-way ANOVA was used followed by Tukey's post hoc test for multiple comparisons or a t test for paired comparisons. Data represent mean ± SEM.
